Related Experiment Video

Updated: Aug 23, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Cardiovascular risk factors and Alzheimer's disease

José A Luchsinger1, Richard Mayeux

  • 1Taub Institute for Research of Alzheimer's Disease and the Aging Brain, Columbia University, PH9E-105, 630 West 168th Street, New York, NY 10032, USA. jal94@columbia.edu

Current Atherosclerosis Reports
|June 12, 2004
PubMed

Insights

Cardiovascular risk factors like diabetes and hypertension may increase Alzheimer's disease risk. Further research is needed to understand these links and develop prevention strategies for this neurodegenerative condition.

Area of Science:

  • Neurology
  • Epidemiology
  • Cardiovascular Medicine

Background:

  • Alzheimer's disease (AD) prevalence is rising globally, with no current cure or prevention.
  • Modifiable cardiovascular risk factors are common in the elderly, but their association with AD remains debated.
  • Potential mechanisms linking cardiovascular health and AD include direct effects and cerebrovascular disease.

Purpose of the Study:

  • To review the evidence linking modifiable cardiovascular risk factors to Alzheimer's disease.
  • To explore potential biological and vascular mechanisms underlying these associations.
  • To identify key risk factors with the strongest supporting evidence.

Main Methods:

  • Literature review of laboratory, clinical, and epidemiological studies.
  • Analysis of existing research on cardiovascular risk factors and Alzheimer's disease.
  • Synthesis of evidence regarding the role of diabetes, hypertension, hyperlipidemia, hyperhomocysteinemia, and smoking.

Main Results:

  • Diabetes and hyperinsulinemia show the most robust evidence linking them to Alzheimer's disease.
  • Hypertension, hyperlipidemia, hyperhomocysteinemia, and smoking are also implicated as potential risk factors.
  • The relationship is likely multifactorial, involving both direct and cerebrovascular pathways.

Conclusions:

  • Modifiable cardiovascular risk factors represent potential targets for Alzheimer's disease prevention strategies.
  • Understanding the interplay between cardiovascular health and brain health is crucial for combating Alzheimer's disease.
  • Further investigation into the specific mechanisms is warranted to inform clinical practice and public health initiatives.

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...